Advertisement
Commentary Free access | 10.1172/JCI35487
1Institute of Virology, University of Ulm, Ulm, Germany. 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Address correspondence to: Frank Kirchhoff, Institute of Virology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Phone: 49-731-50065109; Fax: 49-731-50065131; E-mail: frank.kirchhoff@uniklinik-ulm.de. Or to: Guido Silvestri, University of Pennsylvania School of Medicine, 705 Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, Pennsylvania 19143, USA. Phone: (215) 573-5363; Fax: (215) 573-5366; E-mail: gsilvest@mail.med.upenn.edu.
Find articles by Kirchhoff, F. in: JCI | PubMed | Google Scholar
1Institute of Virology, University of Ulm, Ulm, Germany. 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Address correspondence to: Frank Kirchhoff, Institute of Virology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Phone: 49-731-50065109; Fax: 49-731-50065131; E-mail: frank.kirchhoff@uniklinik-ulm.de. Or to: Guido Silvestri, University of Pennsylvania School of Medicine, 705 Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, Pennsylvania 19143, USA. Phone: (215) 573-5363; Fax: (215) 573-5366; E-mail: gsilvest@mail.med.upenn.edu.
Find articles by Silvestri, G. in: JCI | PubMed | Google Scholar
Published April 22, 2008 - More info
Infection of primates by HIV-1 and SIV induces multiple hematological abnormalities of central hematopoietic origin. Although these defects greatly contribute to the pathophysiology of HIV-1 infection, the molecular basis for altered BM function remains unknown. Here we show that when cynomolgus macaques were infected with SIV, the multipotent potential of their hematopoietic progenitor cells was lost, and this correlated with downregulation of STAT5A and STAT5B expression. However, forced expression of STAT5B entirely rescued the multipotent potential of the hematopoietic progenitor cells. In addition, an accessory viral protein required for efficient SIV and HIV replication and pathogenicity, “Negative factor” (Nef), was essential for SIV-mediated impairment of the multipotent potential of hematopoietic progenitors ex vivo and in vivo. This newly uncovered property of Nef was both conserved between HIV-1 and SIV strains and entirely dependent upon the presence of PPARγ in targeted cells. Further, PPARγ agonists mimicked Nef activity by inhibiting STAT5A and STAT5B expression and hampering the functionality of hematopoietic progenitors both ex vivo and in vivo. These findings have extended the role of Nef in the pathogenicity of HIV-1 and SIV and reveal a pivotal role for the PPARγ/STAT5 pathway in the regulation of early hematopoiesis. This study may provide a basis for investigating the potential therapeutic benefits of PPARγ antagonists in both patients with AIDS and individuals with hematopoietic disorders.
Stéphane Prost, Mikael Le Dantec, Sylvie Augé, Roger Le Grand, Sonia Derdouch, Gwenaelle Auregan, Nicole Déglon, Francis Relouzat, Anne-Marie Aubertin, Bernard Maillere, Isabelle Dusanter-Fourt, Marek Kirszenbaum
HIV-associated hematological abnormalities involve all lineages of blood cells, thus implying that the virus impairs the function of early HSCs. However, the underlying mechanisms of this defect are unknown, particularly since HSCs are largely resistant to HIV-1 infection. In this issue of the JCI, Prost and colleagues show that the viral accessory protein Negative factor (Nef) plays a potentially critical role in the pathogenesis of HIV/SIV-associated hematopoietic dysfunction by affecting the clonogenic potential of HSCs (see the related article beginning on page 1765). Soluble Nef induces PPARγ in uninfected HSCs, thereby suppressing the expression of STAT5A and STAT5B, two factors necessary for proper HSC function. The identification of this novel activity of extracellular Nef defines a new mechanism of HIV/SIV pathogenesis and suggests that approaches aimed at increasing STAT5A and STAT5B expression may be considered in HIV-infected individuals with prominent hematological abnormalities. The results also raise the question of whether dysregulation of hematopoiesis by extracellular Nef plays a role in the development of T cell immunodeficiency and the high levels of chronic immune activation associated with AIDS.
HIV-1 infection causes immunodeficiency by inducing a progressive decline in number of CD4+ helper T cells. However, the mechanisms of HIV/AIDS pathogenesis are complex, as it is still unclear to what extent this progressive CD4+ T cell depletion is caused by direct killing of infected cells or rather by the indirect effects of chronic, generalized immune activation (1). Importantly, HIV infection is also associated with hematopoietic abnormalities characterized by impaired generation and function of cells of all blood lineages (i.e., red blood cells, platelets, and white blood cells). These hematopoietic dysfunctions may cause various levels of cytopenias and also contribute to the development of T cell immunodeficiency (Figure 1) (2). Since all blood cell lineages may be affected, HIV-1 infection apparently deregulates the function of early hematopoietic progenitor cells. This assumption was confirmed by studies showing that CD34+ progenitor cells from HIV-infected patients show reduced growth and differentiation in vitro (3, 4).
Pathogenesis of the hematological abnormalities associated with HIV infection. (A) Schematic demonstrating how bone marrow–derived HSCs develop into precursors of the three main blood cell lineages (erythroid cells, myeloid cells, and platelets) as well as into the T cell precursors that will mature in the thymus and create the pool of circulating naive and memory CD4+ T cells. Ag, antigen. (B) Schematic demonstrating how the soluble viral accessory protein Nef may affect the ability of HSCs to maintain normal levels of peripheral blood cells, based on the new findings of Prost and coworkers reported in this issue of the JCI (14). In addition, Nef may decrease the production of T cell precursors, thus contributing to the peripheral CD4+ T cell depletion observed in HIV-infected individuals that is caused by both the direct effects of HIV on infected cells and the indirect effects of chronic immune activation.
HIV-associated hematological abnormalities seem to be dependent on the level of virus replication, as these abnormalities are severe in late-stage AIDS patients with high viremia but can be corrected by highly active antiretroviral therapy (HAART) (5, 6). The mechanisms underlying these hematological abnormalities are still obscure. While HSCs express low levels of CD4 and CCR5, several studies indicate that they are not susceptible to HIV-1 infection (7–9). Alternative mechanisms that were proposed — although without definitive experimental evidence — include an effect of HIV-1 proteins on uninfected HSCs as well as the hematosuppressive potential of certain proinflammatory cytokines that are produced at high levels during HIV infection (10–13).
The study from Prost and colleagues in this issue of the JCI (14) describes a series of experiments aimed at elucidating the mechanisms causing the hematopoietic abnormalities associated with HIV infection and AIDS. The main conclusion is that the extracellular viral accessory protein Negative factor (Nef) causes hyperactivation of PPARγ, that in turn reduces the expression of the STAT5A/B transcription factors, with consequent functional defects of HSCs (Figure 2). In the first set of experiments, the authors studied SIVmac251-infected macaques and confirmed the existence of three key features of HIV-1–associated defective hematopoiesis: (a) the number of CD34+ HSCs remains normal; (b) the clonogenic potential of these cells declines progressively over the course of infection; and (c) these cells are not infected by the virus. Next, they showed that the HSC defect correlates with low levels of STAT5A and STAT5B expression and, importantly, that overexpression of STAT5B in CD34+ cells by a lentiviral vector rescues the clonogenic function. The role of STAT5A/B in regulating the proliferation, differentiation, and survival of HSCs is well established (15), and the current results reported by Prost and colleagues are consistent with data from murine models showing that knockdown of either STAT5A or STAT5B causes anemia and erythroid defects (16), whereas double knockout of STAT5A and STAT5B proves to be highly anemic in utero and perinatally lethal (17).
Nef-mediated suppression of the clonogenic potential of HSCs. (A) HSC clonogenic potential is dependent on transcriptional activation of STAT5A/B. (B) As reported in the current study by Prost et al. (14), in the setting of HIV and SIVmac infection, Nef induces upregulation of PPARγ, which in turn suppresses the transcription of STAT5A/B, thus causing a reduction of the function and clonogenic potential of HSCs.
Surprisingly, the Prost study (14) shows that extracellular, soluble forms of the HIV and SIVmac Nef proteins may downmodulate STAT5 expression by activating the transcriptional suppressor PPARγ, thus providing a new mechanism to explain the HIV-associated HSC defects (Figure 2B). Of note, this inhibitory effect of soluble Nef on the clonogenic potential of progenitor cells (which the authors elegantly map to a central region of HIV-1 Nef between amino acids 66 and 97) might explain why the hematological abnormalities of HIV-infected patients are correlated with disease progression even though HSCs are not directly infected by the virus. Nef is an early accessory protein of immunodeficiency viruses that is required for efficient viral persistence and strongly accelerates disease progression in HIV-1–infected humans and in experimentally SIV-infected rhesus macaques (18). Nef performs a striking variety of activities that allow the virus to spread efficiently in the infected host and to evade the immune system, including downmodulation of CD4, MHC class I, and in many cases CD3 (most SIV strains and HIV-2, but not HIV-1 and its simian precursors), upregulation of the invariant chain associated with immature MHC class II complexes, and enhancement of viral infectivity and replication (18, 19). Furthermore, Nef interacts with various kinases, modulates cell signaling pathways, and might alter cytokine secretion (20). All these activities of Nef require an intact N-terminal myristoylation signal and are exerted within the virally infected cell. However, Nef is also found in the extracellular environment and reaches concentrations of up to 10 ng/ml in sera of HIV-1–infected individuals (21). Reported effects of extracellular Nef include activation of STAT1 and STAT3 in macrophages (22), induction of apoptosis (23), and immunoglobulin class switching in bystander B cells (24). However, the true in vivo significance of these findings is difficult to assess as the above mentioned results were often obtained using rather artificial experimental conditions characterized by exceptionally high levels of Nef usually produced by bacteria. In this regard, Prost and coworkers (14) demonstrate that sera from SIVmac251-infected macaques can directly suppress STAT5A/B expression and cause HSC dysfunction (and that these effects are reduced by anti-Nef antibodies). These latter results not only support the possibility that the Nef-dependent STAT5A/B suppression occurs at “physiologic” concentrations of this protein, but also raise the question of whether humoral immune responses to Nef, which are detectable in the majority of HIV-1–infected individuals (25), may prevent the development of hematopoietic dysfunction.
As mentioned above, the current study (14) might explain why the severity of the hematologic abnormalities correlates with the levels of virus replication and why functional hematopoiesis is restored by HAART. The observation that extracellular Nef impairs the function of CD34+ progenitor cells in trans also clarifies why HIV-1 does not need to directly infect HSCs to cause hematological abnormalities. However, new interesting questions are raised by the observed results. For example, Prost et al. show that peptides corresponding to residues 66–97 of the central core region of HIV-1 Nef are sufficient to reproduce the defect of HSC function. Although this region is relatively well conserved, the HIV-1 and SIVmac251 Nef sequences differ in 9 of the 31 amino acid residues. Those of other SIVs are frequently even more divergent and — in contrast to HIV-1 Nef proteins — often do not contain an intact Src homology 3–binding (SH3-binding) domain in this region, raising the question of whether this Nef activity is conserved among the different groups of primate lentiviruses. This question is crucial as SIV infection of natural hosts such as the Sooty mangabeys or African green monkeys is not associated with immunodeficiency or impaired bone marrow function despite chronically high levels of virus replication (26). From this perspective, it will be interesting to elucidate whether this effect of Nef is mainly an indicator of suboptimal virus-host adaptation in the evolutionarily recent human and experimental rhesus macaque hosts or indeed a conserved strategy of primate lentiviruses to evade the host immune system by suppressing the clonogenic potential of HSCs.
While the current study by Prost and colleagues (14) is of great interest, much work will be required to define the mechanism by which extracellular Nef induces PPARγ and to determine whether the levels of Nef in blood and bone marrow are sufficient to impair HSC function during HIV infection. It will also be important to better understand (a) to what extent this impaired hematopoiesis contributes to the T cell immunodeficiency associated with progression to AIDS, and (b) how these hematological defects relate to the state of chronic hyperimmune activation that seems to drive the loss of CD4+ T cells and progression to immunodeficiency in HIV-infected individuals. As STAT5 signaling plays a critical role in T cell development and function (27), an additional question is whether Nef also affects T cell homeostasis by suppressing STAT5A/B function in other, more mature T cell subsets (28). From a clinical point of view, the results of Prost and colleagues may potentially identify Nef and/or PPARγ as target for new therapeutic approaches aimed at preventing or correcting the hematologic abnormalities associated with HIV-1 infection. On the other hand, the identification of PPARγ as a suppressor of HSC function might have implications for the use of PPARγ agonists, such as glitazones, in the treatment of diabetes.
F. Kirchhoff thanks the Wilhelm-Sander Foundation, the Deutsche Forschungsgemeinschaft, and the NIH (R01AI067057) for support.
Address correspondence to: Frank Kirchhoff, Institute of Virology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Phone: 49-731-50065109; Fax: 49-731-50065131; E-mail: frank.kirchhoff@uniklinik-ulm.de. Or to: Guido Silvestri, University of Pennsylvania School of Medicine, 705 Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, Pennsylvania 19143, USA. Phone: (215) 573-5363; Fax: (215) 573-5366; E-mail: gsilvest@mail.med.upenn.edu.
Nonstandard abbreviations used: Nef, Negative factor.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J. Clin. Invest.118:1622–1625 (2008). doi:10.1172/JCI35487.
See the related article at Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARγ/STAT5 signaling pathway in macaques.